UCB (OTCMKTS:UCBJF) Sets New 52-Week High - Still a Buy?

Key Points

• UCB SA shares reached a new 52-week high of $218.19 during trading, closing at the same price after previously being at $211.99.
• Morgan Stanley has upgraded UCB to an "overweight" rating, indicating a positive outlook on the company's stock.
• The company's primary products include treatments for neurological and immunological diseases, highlighting its focus on biopharmaceuticals in critical health areas.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $218.19 and last traded at $218.19, with a volume of 26 shares changing hands. The stock had previously closed at $211.99.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded UCB to an "overweight" rating in a research report on Monday, June 23rd.

UCB Price Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock's 50-day moving average is $196.86 and its 200-day moving average is $184.43.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.